Prestige Consumer Healthcare reported first quarter fiscal 2027 revenue of $265.7 million, up 6.5% year-over-year, with organic sales growth of 3.2%. Adjusted diluted earnings per share reached $0.98, compared to $0.95 in the prior year period. The company closed acquisitions of Breathe Right and LaCorium Health in June and July, respectively. Breathe Right contributed $5.9 million to quarterly revenue. First quarter adjusted free cash flow hit a record $83.7 million, up from $78.2 million the previous year. The company's net debt position stood at approximately $2 billion as of 30 June 2026. Prestige raised its full-year fiscal 2027 outlook to reflect the acquisitions, now expecting revenue of $1.29 billion to $1.315 billion and adjusted diluted EPS of $4.55 to $4.65.

Prestige Consumer Healthcare has closed its largest acquisition, purchasing the Breathe Right brand and other over-the-counter labels from Foundation Consumer Healthcare for $1.045 billion. The deal, completed on 15 June, brings in approximately $200 million in annual revenue and $95 million in EBITDA. The acquisition includes Breathe Right nasal strips, Dimetapp children's cough medicine and Anbesol oral pain relief. Breathe Right is now Prestige's largest brand, with potential expansion beyond sleep wellness into athletic performance and allergy relief. CEO Ron Lombardi plans to replicate the company's successful Dramamine strategy, which transformed that brand from a motion sickness remedy into a broader nausea treatment. Prestige focuses on "category synonymous" brands, with roughly 64% of revenues coming from brands holding number one positions in their categories.

Canaccord Genuity reduced its price target on Prestige Consumer Healthcare Inc. from $86 to $72 whilst maintaining a Buy rating, following weaker fourth-quarter results. The downgrade was attributed to softness in the eye care segment and additional pressure related to the Iran conflict. Separately, Prestige Consumer Healthcare announced on 13 May a definitive agreement to acquire LaCorium Health for approximately $150 million in cash. LaCorium generated roughly $40 million in revenue over the trailing twelve months ending 28 February and is expected to contribute around $12 million in EBITDA post-integration. The transaction is expected to close during the second quarter of fiscal 2027, subject to standard closing conditions.